RxDoctor Payments Data

Camille Anise, MD

Family Medicine · Sarasota, FLNPI 1790949113

Payments from drug & device makers

$2,059in general payments, 2019–2025

Across 99 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$424
  • Lilly USA, LLC$292
  • Novo Nordisk$223
  • Amarin Pharma, Inc.$185
  • Pfizer$138
  • GSK$136
  • plus $661 from 14 others

What the payments were for

  • Food & beverage$2,03299%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,059 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$35,466
Medicare patients
124
Services billed
487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban55$61,112
OzempicSemaglutide19$19,293
XareltoRivaroxaban12$17,265
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,736
Soliqua 100-33Insulin Glargine/Lixisenatide11$8,513
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$6,899
LantusInsulin Glargine,hum.Rec.Anlog23$5,174
Albuterol Sulfate HfaAlbuterol Sulfate130$4,143
Gabapentin193$3,726
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,576
Wixela InhubFluticasone Propion/Salmeterol28$2,723
Levothyroxine Sodium266$2,485
Atorvastatin Calcium332$2,248
Omeprazole219$2,114
Lisinopril391$1,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$61,11255 claims
Novo NordiskOzempic$223$19,29319 claims
Johnson & JohnsonXarelto$30$17,26512 claims
GSKTrelegy Ellipta$136$13,73617 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$58$13,68734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →